[
    [
        {
            "time": "2019-04-30",
            "original_text": "Pre-Market Earnings Report for April 30, 2019: MA, PFE, MRK, MCD, LLY, CHTR, GE, COP, GM, SPG, ECL, HCA",
            "features": {
                "keywords": [
                    "earnings",
                    "LLY",
                    "PFE",
                    "MRK"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pre-Market Earnings Report for April 30, 2019: MA, PFE, MRK, MCD, LLY, CHTR, GE, COP, GM, SPG, ECL, HCA",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "Beaten-down health-care companies join Apple and Google in earnings parade",
            "features": {
                "keywords": [
                    "health-care",
                    "earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Beaten-down health-care companies join Apple and Google in earnings parade",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates",
            "features": {
                "keywords": [
                    "Drug",
                    "Biotech",
                    "Q1",
                    "Earnings"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "The obscure advisory committees at the heart of the U.S. drug pricing debate",
            "features": {
                "keywords": [
                    "advisory",
                    "committees",
                    "drug",
                    "pricing"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "government"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The obscure advisory committees at the heart of the U.S. drug pricing debate",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice",
            "features": {
                "keywords": [
                    "Growth",
                    "Stock",
                    "Lilly",
                    "LLY"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "Tomorrow Is Earnings Day for Big Pharma. Here’s What to Watch.",
            "features": {
                "keywords": [
                    "Earnings",
                    "Big Pharma"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Tomorrow Is Earnings Day for Big Pharma. Here’s What to Watch.",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-30",
            "original_text": "A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug",
            "features": {
                "keywords": [
                    "Cosentyx",
                    "Novartis",
                    "Immunology",
                    "Drug"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]